Anticoagulant News and Research RSS Feed - Anticoagulant News and Research

Poor blood pressure control increases stroke risk in patients with atrial fibrillation

Poor blood pressure control increases stroke risk in patients with atrial fibrillation

Poor blood pressure control among patients with atrial fibrillation is associated with a 50-percent increased risk of stroke, according to an analysis presented by Duke Medicine researchers. [More]

Genetic testing could help determine drug dosage, reduce side effects

Usually pharmaceutical companies determine the drug dosage just as a mean value. This amount may be too much for patients who absorb the substance faster, and too little for those with a slower metabolism. [More]
New case study reveals how to safely switch between anticoagulants for stroke prevention

New case study reveals how to safely switch between anticoagulants for stroke prevention

With the availability of newer oral anticoagulants, the latest online case study from NPS MedicineWise helps health professionals navigate this changing area and understand the range of treatment options for managing stroke prevention in people with non-valvular atrial fibrillation. [More]
ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension. [More]
Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. [More]
Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients. [More]
Regado receives Fast Track designation from FDA for REG1

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. [More]
New optical device may help docs to diagnose blood coagulation status in near real time

New optical device may help docs to diagnose blood coagulation status in near real time

​Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body's natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure. [More]
AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

An updated guideline from the American Academy of Neurology recommends that people with nonvalvular atrial fibrillation, or irregular heartbeat, take oral anticoagulants, a type of blood thinner pill, to prevent stroke. [More]
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013. [More]
Researchers use cardiac monitor to assess atrial fibrillation after cryptogenic stroke

Researchers use cardiac monitor to assess atrial fibrillation after cryptogenic stroke

Larry Ambrose woke up one night, wandered into his kitchen but couldn't completely read the time on his microwave. A few days later when he noticed his blood pressure was unusually high, he went to the hospital and was diagnosed as having a stroke. [More]
Study shows one-quarter of high risk patients do not receive anticoagulants after ablation of AF

Study shows one-quarter of high risk patients do not receive anticoagulants after ablation of AF

​One-quarter of high risk patients do not receive anticoagulants after ablation of atrial fibrillation (AF), according to the latest survey of European practice. [More]

Study reveals overall success rate of AF ablation in Europe

One-quarter of high risk patients do not receive anticoagulants after ablation of atrial fibrillation (AF), according to the latest survey of European practice. [More]
FDA accepts Regado Biosciences' IND application for REG2

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future. [More]
Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association. [More]
Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin is still overprescribed for stroke prevention in atrial fibrillation (AF) despite the potential for dangerous side effects, according to research published today. [More]
Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients. [More]
Study shows that anticoagulant medicine appears to protect patients against stroke

Study shows that anticoagulant medicine appears to protect patients against stroke

​Heart palpitations. Shortness of breath. Tiredness. More and more people can recognise the symptoms of atrial fibrillation, which is one of the most common types of heart disease. [More]
Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency. [More]
ESC presents results of pilot registry on management and treatment of AF in Europe

ESC presents results of pilot registry on management and treatment of AF in Europe

Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal. [More]